Biochemical Reaction Networks and Blood Clotting

Similar documents
Coagulation under Flow: The Influence of Flow-Mediated Transport on the Initiation and Inhibition of Coagulation

Blood coagulation and fibrinolysis. Blood clotting (HAP unit 5 th )

Primary Exam Physiology lecture 5. Haemostasis

Part IV Antithrombotics, Anticoagulants and Fibrinolytics

Blood clotting. Subsequent covalent cross-linking of fibrin by a transglutaminase (factor XIII) further stabilizes the thrombus.

On a Minimal Mathematical Model for Regulation of Factor Va by Activated Protein C

Introduction to coagulation and laboratory tests

Ch. 45 Blood Plasma proteins, Coagulation and Fibrinolysis Student Learning Outcomes: Describe basic components of plasma

The Influence of Hindered Transport on the Development of Platelet Thrombi Under Flow

WHITE PAPERS PRESENTATION VIDEO DOCUMENTATION EXPERIMENT WO NDCLOT. The WoundClot Principals for Effective Bleeding Control PRESENTATION

Chapter 1. General introduction

Chapter 1 Introduction

THROMBOTIC DISORDERS: The Final Frontier

Bleeding and Haemostasis. Saman W.Boskani HDD, FIBMS Maxillofacial Surgeon

Chapter 3. Haemostatic abnormalities in patients with liver disease

Hemostasis. Clo)ng factors and Coagula4on NORMAL COAGULATION. Overview of blood coagula4on. The Cascade Theory 5/1/12. Clot

Diagnosis of hypercoagulability is by. Molecular markers

Continuing Medical Education

4/23/2009. September 15, 2008

PHASES OF HAEMOSTASIS

Outline Anti-coagulant and anti-thrombotic drugs Haemostasis and Thrombosis Year 3 Dentistry

Hemostasis. Learning objectives Dr. Mária Dux. Components: blood vessel wall thrombocytes (platelets) plasma proteins

Modeling of human factor Va inactivation by activated protein C

What are blood clots?

Inherited Thrombophilia Testing. George Rodgers, MD, PhD Kristi Smock MD

Mathematical Model of Serine Protease Inhibition in the Tissue Factor Pathway to Thrombin*

Hemodynamics. Objectives. Filtration across the endothelium 1/17/2017. K[(P cap - P int )-σ(π cap π int )]

This slide belongs to iron lecture and it is to clarify the iron cycle in the body and the effect of hypoxia on erythropoitein secretion

Disseminated Intravascular Coagulation. M.Bahmanpour MD Assistant professor IUMS

Anatomy and Physiology

Hemostasis and Thrombosis

Thrombosis. Jeffrey Jhang, M.D.

Do some of physiotherapy and rehabilitation programs improve the health state of patients suffering from cerebral clot?

Thursday, February 26, :00 am. Regulation of Coagulation/Disseminated Intravascular Coagulation HEMOSTASIS/THROMBOSIS III

Factor VIIa-Antithrombin complex levels and Factor Xa generation in CAD patients

ADVANCES IN ANTICOAGULATION

Hemostasis and. Blood Coagulation

Cover Page. The handle holds various files of this Leiden University dissertation.

Coagulation Pathway and Physiology

Coagulation Pathway and Physiology

Blood (II) Huawei Liang, PhD

Human coagulation factor Xa, FXa ELISA Kit

Agent Dose MoA/PK/Admin Adverse events Disadvantages Protamine Heparin: 1mg neutralizes ~ 100 units Heparin neutralization in ~ 5 min

Important Considera/ons for Coagula/on Tests on Children and Neonates

Emergency Blood and Massive Transfusion: The Surgeon s Perspective. Transfusion Medicine Update September 16 17, 2009

ACQUIRED COAGULATION ABNORMALITIES

COAGULATION INHIBITORS LABORATORY DIAGNOSIS OF PROTHROMBOTIC STATES REGULATION OF. ANTICOAGULANT PROTEIN DEFICIENCY Disease entities COAGULATION

Platelet-fibrin clot. 50Kd STEMI. Abciximab. Video of a IIb/IIIa inhibitor in action. Unstable Angina and non-stsegment

New drugs for anticoagulation so much choice, how do they compare? Dr Patrick Kesteven Newcastle

Chapter 11. Lecture and Animation Outline

SELECTED READINGS ORAL AND MAXILLOFACIAL SURGERY HEMOSTATIS: A CLINICAL REVIEW OF PHYSIOLOGY, PATHOLOGY, PHARMACOLOGY, AND PERI-OPERATIVE MANAGEMENT

Cofactor Control of a Vital Enzymatic Reaction;the Effect of Factor Va on Thrombin Formation During Blood Coagulation

HEME 10 Bleeding Disorders

UNIT VI. Chapter 37: Platelets Hemostasis and Blood Coagulation Presented by Dr. Diksha Yadav. Copyright 2011 by Saunders, an imprint of Elsevier Inc.

Thrombosis. By Dr. Sara Mohamed Abuelgasim

Recent experimental and clinical studies have shown that

Anticoagulants. Pathological formation of a haemostatic plug Arterial associated with atherosclerosis Venous blood stasis e.g. DVT

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) CORE SPC FOR HUMAN PROTHROMBIN COMPLEX PRODUCTS (CPMP/BPWG/3735/02)

A Brief History of the World of Anticoagulation

Chapter 19 Blood Lecture Outline

A Model for the Tissue Factor Pathway to Thrombin

Physiology of. The Blood hemostasis. By prof. Israa f. jaafar

Thrombophilia. Diagnosis and Management. Kevin P. Hubbard, DO, FACOI

Hemostasis and fibrinolysis the hemostatic balance

Topics of today lectures: Hemostasis

When referring to this work, the full bibliographic details must be given as follows:

Chapter 19. Hemostasis

-Hashim ahmed is the one who wrote this sheet. I just edited it according to our record.

DVT Pathophysiology and Prophylaxis in Medically Hospitalized Patients. David Liff MD Oklahoma Heart Institute Vascular Center

HEMOSTASIS/THROMBOSIS II

Prothrombin Complex Concentrate- Octaplex. Octaplex

True/False: Idarucizumab can be utilized for the management of bleeding associated with dabigatran.

Supplementary table to Bennett et al. Peripheral arterial disease and Virchow s triad (Thromb Haemost 2009; 101.6)

COPYRIGHTED MATERIAL. Overview of h emostasis. Kathleen Brummel Ziedins and Kenneth G. Mann University of Vermont, College of Medicine, VT, USA

Recombinant factor VIIa: Hype or hope? Jed Gorlin MD, MBA

General approach to the investigation of haemostasis. Jan Gert Nel Dept. of Haematology University of Pretoria 2013

Mousa Suboh. Osama Alzoubi (OZ) Malik Zuhlof. 1 P a g e

Blood products and plasma substitutes

PROTEÓMICA y SAF. Maria Josė Cuadrado Lupus Research Unit St. Thomas Hospital London UK

Discuss the role of idarucizumab for the management of bleeding associated with dabigatran

BLEEDING DISORDERS Simple complement:

CLINICAL FELLOWSHIP PROGRAM IN COAGULATION

Branch of medicine that deals with blood, its formation and disorders is called. Three main functions of cardiovascular system are,, and.

Bleeding and Thrombotic Disorders. Kristine Krafts, M.D.

Reversal of Novel Oral Anticoagulants. Angelina The, MD March 22, 2016

Six Types of Enzyme Catalysts

Pathology note 8 BLEEDING DISORDER

THE fundamental concepts of blood coagulation formulated almost 50 years

Positive Feedback Loops for Factor V and Factor VII Activation Supply Sensitivity to Local Surface Tissue Factor Density During Blood Coagulation

Hemostasis. Coagulation vs anticoagulation

Modelling of the Blood Coagulation Cascade in an In Vitro Flow System.

Elucidating the interaction between the Fragment 2 domain of Prothrombin and Factor Va

DIC. Bert Vandewiele Fellow Critical Care 23 May 2011

Step 2. Common Blood Tests, and the Coulter Counter Readout

The New England Journal of Medicine HIGH LEVELS OF COAGULATION FACTOR XI AS A RISK FACTOR FOR VENOUS THROMBOSIS

Supra-Regional Audit Anticoagulation in Palliative Care. 4 th March Denise Farrance

Recent studies have found that elevated levels of coagulation

Coagulation an Overview Dr.Abdolreza Abdolr Afrasiabi Thal assem a & Heamophili hilia G ene i tic R esearc C en er Shiraz Medical Medic University

Reprinted in the IVIS website with the permission of the ACVP and ASVCP

Transcription:

Biochemical Reaction Networks and Blood Clotting Yasmeen Hussain, Aaron Fogelson Abstract Following an injury to the walls of a blood vessel, platelet aggregation and blood coagulation are induced. Through a series of enzymatic and biochemical interactions, a blood clot is formed. Using ordinary differential equations with mass action and Michaelis-Menton kinetics to describe these interactions and computer programs like Fortran and Matlab, we are able to model blood clot formation and maintenance, both spatially-dependent biochemical reaction networks. Biology Background Various chemical components are involved in blood clot formation. Enzymes, like VIIa, IXa, and Xa, work in conjunction with cofactors like TF (tissue factor), VIIIa, and Va. The processes that the enzymes and cofactors facilitate are also affected by inhibitors such as APC (activated protein C), which inhibits VIIIa and Va, TFPI (tissue factor pathway inhibitor), which inhibits the actions of TF and a VIIa:Xa complex, and ATIII (antithrombin III), which inhibits thrombin, IXa, and Xa. As shown in the Figure 1, there are various interactions that take place between enzymes, cofactors, and inhibitors. Some of these processes can occur in solution, while others can only take place in certain locations on the subendothelium or on an activated platelet. Thrombin is the most crucial component of the blood clotting system, as its presence both renders platelets active and breaks fibrinogen into fibrin, the mesh base of a blood clot. Thrombin also acts as an enzyme processor in solution, along with Xa. The tenase complex of VIIIa:IXa and the prothrombinase Va:Xa complex act only when bound to an activated platelet. One other complex, TF:VIIa, acts only when attached to the subendothelium. Enzymatic processes in this system are outlined in Table 1. Mathematical Model Certain aforementioned enzyme-factor complexes act as processors only when they are bound to specific blood vessel locations. Complications arise when we take into account the actual density of binding sites in a given location. Binding site density, along with enzyme concentration, shear rate, platelet count, and material-inherent surface reactivity, add complexity and realism to the traditional mass-action and Michaelis- Menton mathematical models.

Each mathematical model is constructed with its own assumptions. The model initially utilized in this project assumed that all solution materials are well-mixed, that protein flow rate is proportional to protein concentration differences, that platelet transport is different from enzyme transport due to platelet thickness, that unactivated platelets are free to flow out while activated platelets stack and create a difference of rate constants due to volume, and that binding sites can harbor competition, sharing, or specificity. Modeling Experiments The unaltered model used in this project was originally created in Fortran with 63 ordinary differential equations. Using this mathematical model, it is possible to find differences in the system s reactions to changes. When parameter values, generally concentrations and rate constants, and shear rate, the gradient of velocity is a flowing material (in inverse seconds), are standardized, it is possible to compare the differences between a system in which platelet deposit blocks TF:VIIa activity and in which it does not (Figures 2, 3) Experiments such as these are useful for determining the actual effect of variable concentrations of clotting components on normal systems. However, there is the other aspect of the abnormal system. In diseases like hemophilia, the system may be lacking a chemical or physical component crucial to the blood clotting process (Figure 4). Another thing that can be altered is the shear rate. In Figure 5, thrombin concentration as dependent on TF density on the subendothelium is shown at different shear rates. Model Modifications The model discussed is based off of a great deal of biological background and uses some of the most powerful tools of mathematical modeling. However, this model designed by Kuharsky and Fogelson is by no means entirely accurate. In order to make it more representative of the actual biological process, other components can be added. Years later, Fogelson and Tania updated the other model. They added more complex APC inhibitor interaction and alternative TFPI interaction which assumed a finite rate of inhibitor unbinding and a differing Xa/TF:VIIa post-activation action. Also, a second shell was added to create the endothelial zone, an area right above the reaction zone where molecules are more susceptible to being carried downstream. Interaction between the reaction and endothelial zones is also included in the newer model. This model showed various differences in results. Starting with the same parameter values, enzyme concentrations appeared to change (Figure 6). It is also possible to see the result of the additional zone in Figure 7. Future Work

The project thus far has consisted of learning the workings of the enzymatic biological system involved in blood clotting by reading journal articles, becoming familiar with previous models, and converting the Fortran code to Matlab for ease of modification and further work. The goal is to, after obtaining a working Matlab model, add other interactions such as that of enzyme XI with soluble tissue factors, account more consistently for the effects of blood flow, adjust enzyme/cofactor/inhibitor levels, and explore the complex intervention of immune response. These additions, especially the extra enzyme, are subjects of controversy in the clotting community and have never before been included in coagulation models.

Figures and Tables Figure 1- Enzymatic Interactions Location Input Processor Product Act. Platelet X Tenase VIIIa:IXa Xa Act. Platelet Prothrombin Prothrombinase Va:Xa Thrombin Solution V Thrombin Va Solution VII Thrombin VIIa Solution VIII Thrombin VIIIa Solution V Xa Va Solution VII Xa VIIa Solution VIII Xa VIIIa Subendo. IX TF:VIIa IXa Subendo. X TF:VIIa Xa Table 1- Enzymatic Processes

Figure 2- Platelet Deposit Blocks TF:VIIa Activity Figure 3- Platelet Deposit Does Not Block TF:VIIa Activity

Figure 4- Hemophilia Comparison Figure 5- Shear Rate Comparison

Figure 6- Enzyme Concentrations Figure 7- Zone Comparison

References Fogelson, Aaron L, and Nessy Tania. "Coagulation under Flow: The Influence of Flow- Mediated Transport on the Initiation and Inhibition of Coagulation." Pathophysiology of Haemostasis and Thrombosis 34 (2005): 91-108. Goldbeter, Albert, and Daniel E Koshland. "An amplified sensitivity arising from covalent modification in biological systems." Proc. Natl. Acad. Sci. USA 78.11 (Nov. 1981): 6840-6844. Kuharsky, Andrew L, and Aaron L Fogelson. "Surface-Mediated Control of Blood Coagulation: The Role of Binding Site Densities and Platelet Deposition." Biophysical Journal 80 (Mar. 2001): 1050-1074.